Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1986 1
1987 1
1992 1
1993 3
1994 1
1999 1
2000 2
2002 5
2003 4
2004 9
2005 3
2006 5
2007 2
2008 5
2009 3
2010 2
2011 1
2012 1
2013 1
2014 2
2015 7
2016 10
2017 5
2018 2
2019 5
2020 10
2021 6
2022 9
2023 6
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Scalp Psoriasis.
Ghafoor R, Patil A, Yamauchi P, Weinberg J, Kircik L, Grabbe S, Goldust M. Ghafoor R, et al. Among authors: yamauchi p. J Drugs Dermatol. 2022 Aug 1;21(8):833-837. doi: 10.36849/JDD.6498. J Drugs Dermatol. 2022. PMID: 35946971 Review.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Bieber T, et al. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. N Engl J Med. 2021. PMID: 33761207 Clinical Trial.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K. Warren RB, et al. Among authors: yamauchi p. N Engl J Med. 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23. N Engl J Med. 2021. PMID: 33891379 Clinical Trial.
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, Bhatia N, Del Rosso JQ, Ferris LK, Green LJ, Hebert AA, Jones T, Kempers SE, Pariser DM, Yamauchi PS, Zirwas M, Albrecht L, Devani AR, Lomaga M, Feng A, Snyder S, Burnett P, Higham RC, Berk DR. Lebwohl MG, et al. Among authors: yamauchi ps. JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632. JAMA. 2022. PMID: 36125472 Free PMC article.
Antihistamines in Psoriasis.
Shivakumar S, Mueller SM, Yamauchi PS, Weinberg JM, Kircik L, Szepietowski JC, Goldust M. Shivakumar S, et al. Among authors: yamauchi ps. J Drugs Dermatol. 2021 Aug 1;20(8):844-847. doi: 10.36849/JDD.5966. J Drugs Dermatol. 2021. PMID: 34397204 Review.
Treatment of Nail Psoriasis.
Kassir M, Kircik L, Weinberg J, Fatima F, Yamauchi P, Lotti T, Wollina U, Grabbe S, Goldust M. Kassir M, et al. Among authors: yamauchi p. J Drugs Dermatol. 2022 Feb 1;21(2):146-150. doi: 10.36849/jdd.4969. J Drugs Dermatol. 2022. PMID: 35133106 Review.
One-Year Pharmacovigilance Update of Brodalumab.
Lebwohl M, Leonardi C, Wu JJ, Yamauchi P, Rawnsley N, Merchant M, Alexander B, Jacobson A. Lebwohl M, et al. Among authors: yamauchi p. J Drugs Dermatol. 2020 Aug 1;19(8):807-808. doi: 10.36849/JDD.2020.5138. J Drugs Dermatol. 2020. PMID: 32845586 No abstract available.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Augustin M, et al. Among authors: yamauchi p. Br J Dermatol. 2022 Jun;186(6):942-954. doi: 10.1111/bjd.20971. Epub 2022 Apr 8. Br J Dermatol. 2022. PMID: 34981829 Clinical Trial.
111 results